These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 30194622

  • 1. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [Abstract] [Full Text] [Related]

  • 4. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [Abstract] [Full Text] [Related]

  • 5. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X, Connock M, Tsertsvadze A, Cummins E, Melendez-Torres GJ, Royle P, Clarke A.
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [Abstract] [Full Text] [Related]

  • 6. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA.
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [Abstract] [Full Text] [Related]

  • 7. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V, Zhong L, Narsipur N, Hays E, Tran DK, Rosario K, Wilson L.
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [Abstract] [Full Text] [Related]

  • 9. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
    Loke L, Lee SC, Pearce F, Ng K, Aziz MIA.
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1308. PubMed ID: 33085843
    [Abstract] [Full Text] [Related]

  • 11. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.
    Ann Oncol; 2018 Jul 01; 29(7):1541-1547. PubMed ID: 29718092
    [Abstract] [Full Text] [Related]

  • 12. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep 01; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 13. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J.
    Pharmacoeconomics; 2023 Jul 01; 41(7):741-750. PubMed ID: 36952138
    [Abstract] [Full Text] [Related]

  • 14. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.
    N Engl J Med; 2016 Nov 03; 375(18):1738-1748. PubMed ID: 27717303
    [Abstract] [Full Text] [Related]

  • 15. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E.
    Pharmacoeconomics; 2015 May 03; 33(5):457-66. PubMed ID: 25616671
    [Abstract] [Full Text] [Related]

  • 16. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C, Sideris E, Wade R, Moe-Byrne T, Eastwood A, McKenna C.
    Pharmacoeconomics; 2015 Dec 03; 33(12):1269-79. PubMed ID: 26043718
    [Abstract] [Full Text] [Related]

  • 17. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
    Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ.
    Pharmacoeconomics; 2016 Jan 03; 34(1):23-31. PubMed ID: 26314282
    [Abstract] [Full Text] [Related]

  • 18. Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.
    Giuliani J, Bonetti A.
    Clin Breast Cancer; 2019 Aug 03; 19(4):e519-e521. PubMed ID: 30858036
    [Abstract] [Full Text] [Related]

  • 19. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R, Wyld L.
    Pharmacoeconomics; 2018 Jan 03; 36(1):29-38. PubMed ID: 28770452
    [Abstract] [Full Text] [Related]

  • 20. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.
    Breast Cancer Res Treat; 2018 Feb 03; 168(1):127-134. PubMed ID: 29164421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.